SCHEMBL2270541

SCHEMBL2270541

OC1(c2cc(F)cc(Cl)c2)CCNCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 4/20 0.56
METAP2 P50579 1/20 0.37
TRPM5 Q9NZQ8 7/20 0.35
MAPKAPK2 P49137 1/20 0.34
TRPM4 Q8TD43 2/20 0.34
CCNT1 O60563 1/20 0.32
CDK9 P50750 1/20 0.32
HTR1A P08908 1/20 0.32
DRD1 P21728 1/20 0.32
DRD5 P21918 1/20 0.32
SLC6A2 P23975 1/20 0.32
HTR2A P28223 1/20 0.32
SLC6A4 P31645 1/20 0.32
HTR7 P34969 1/20 0.32
HRH1 P35367 1/20 0.32
DRD3 P35462 1/20 0.32
HTR2B P41595 1/20 0.32
TACR1 P25103 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
SSTR5 P35346 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3110638 0.90 DRD2 (0.45) DRD2METAP2TRPM5TRPM4CCNT1
SCHEMBL373752 0.87 DRD2 (0.50) DRD2METAP2CCNT1CDK9SLC6A2
SCHEMBL655758 0.87 DRD2 (0.66) DRD2MAPKAPK2SLC6A2SLC6A4TACR1
SCHEMBL1331093 0.86 DRD2 (0.38) DRD2METAP2TRPM5TRPM4SLC6A2
Hydrochloric Acid SCHEMBL973810 0.85 DRD2 (0.48) DRD2METAP2CCNT1CDK9SLC6A2
Hydrochloric Acid SCHEMBL30005276 0.85 DRD2 (0.63) DRD2MAPKAPK2SLC6A2SLC6A4TACR1
SCHEMBL2273078 0.79 OPRM1 (0.50) DRD2MAPKAPK2CCNT1CDK9SLC6A2
SCHEMBL2269033 0.77 S1PR2 (0.41) DRD2SLC6A4TACR1
SCHEMBL3111623 0.77 DRD2 (0.52) DRD2MAPKAPK2SLC6A2HTR2ASLC6A4
SCHEMBL3109594 0.77 DRD2 (0.39) DRD2METAP2CCNT1CDK9SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023102022-A1 4-PHENYL-2-(1H-1,2,3-TRIAZOL-4-YL)PIPERIDIN-4-OL DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-06-08 WO disclosed
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 EP disclosed
US-7994196-B2 Indazole compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-09 US disclosed
US-7994196-B2 Indazole compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-09 US disclosed
US-7994196-B2 Indazole compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-09 US disclosed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US disclosed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US disclosed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US disclosed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173537-A1 Indazole compound and pharmaceutical use thereof CYP3A5, CYP3A43, TP53 DRD2 3805/4885METAP2 4184/4885TRPM5 878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.